top of page

Publications

2026 up-to-date

1. Kim JM*, Yang YS, Xie J, Kang CM, Cho YC, Park KH, Gong F, Sato T, Kim BJ, Gao G, and Shim JH*. USP24-dependent STAT2 stabilization mediates physiologic and pathologic bone formation. Cell Death Dis. accepted. *co-corresponding author. 

This research identifies the deubiquitinating enzyme USP24 as a pivotal regulator of osteogenesis that stabilizes STAT2 to promote bone formation. The study elucidates how the USP24-STAT2 axis modulates BMP signaling, driving both physiological skeletal development and the pathogenesis of heterotopic ossification (HO). The effective mitigation of ectopic bone formation through USP24 silencing in FOP mouse models underscores the therapeutic potential of targeting this signaling pathway to treat debilitating ossification disorders.

2. Kang CM and Kim JM. The posttranslational modification landscape of transcription factors in osteoblast differentiation and bone formation. Life Sci. 2026 Jun 1:394:124365.

This review highlights the critical roles of master transcription factors RUNX2 and Osterix in driving osteoblast commitment, proliferation, differentiation and bone homeostasis. Also it focuses on how posttranslational modifications, such as phosphorylation, ubiquitination and acetylation modulates interactions and stability of these factors during osteoblast development. Ultimately the paper suggests that targeting PTM-mediated regulatory pathways has therapeutic potential for treating various skeletal disorders.​

2020-2025

1. Kim JM*, Stavre Z*, Yang YS, Nündel K, Chaugule S, Sato T, Park KH, Gao G, Gravallese E, and Shim JH. Schnurri-3 Inhibition Suppresses Bone and Joint Damage in Models of Rheumatoid Arthritis. Proc. Natl. Acad. Sci. U.S.A. 2023 May 9;120(19):e2218019120.
*co-first author.

2. Oh WT, Yang YS, Xie J, Ma H, Kim JM, Park KH, Oh DS, Park-Min KH, Greenblatt MB, Gao G, and Shim JH. WNT-modulating gene silencers as novel gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. Mol Ther. 2023 Feb 1;31(2):435-453. 

3. Yang YS*, Kim JM*, Xie J*, Chaugule S, Lin C, Ma H, Hsiao E, Hong J, Chun H, Shore E, Kaplan F, Gao G, and Shim JH. Suppression of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva Using AAV Gene Delivery. Nat Commun. 2022 Oct 19;13(1):6175. *co-first author. *Selection for Editors’ highlights.

4. John AA, Xie J, Yang YS, Kim JM, Lin C, Ma H, Gao G, and Shim JH. AAV-mediated delivery of osteoblast/osteoclast-regulating miRNAs for osteoporosis therapy. Mol Ther Nucleic Acids. 2022 Sep 13;29:296-311.  

5. Kim JM, Yang YS, Hong J, Chaugule S, Chun H, van der Meulen MCH, Xu R, Greenblatt MB, and Shim JH. Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway. Elife. 2022 Aug 17;11:e78069.  

6. Kim JM, Yang YS, Xie J, Lee O, Kim J, Hong J, Boldyreff B, Filhol O, Chun H, Greenblatt MB, Gao G, and Shim JH. Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes. Cell Death Differ. 2022 Aug;29(8):1625-1638. *Selection for Monthly Readers’ Choice. 

7. Greenblatt MB, Shim JH, Bok S, and Kim JM. The Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathway in Osteoblasts. J Bone Metab. 2022 Feb;29(1):1-15.  

8. Chaugule S, Kim JM, Yang YS, Knobeloch KP, He X, and Shim JH. Deubiquitinating Enzyme USP8 Is Essential for Skeletogenesis by Regulating Wnt Signaling. Int J Mol Sci. 2021 Sep 24;22(19).

9.  Kim JM, Lin C, Stavre Z, Greenblatt MB, and Shim JH. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020 Sep 10; 9(9), 2073. Review article. *BEST PAPER AWARD 

10. Yang YS, Xie J, Chaugule S, Wang D, Kim JM, Kim J, Tai PWL, Seo SK, Gravallese E, Gao G, and Shim JH. Bone-targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy. Mol Ther Methods Clin Dev. 2020 Jun 12;17:922-935.

11. Kim JM, Yang YS, Park K, Ge X, Xu R, Na L, Song M, Chun H, Bok S, Charles JF, Fihol-Cochet O, Boldyreff B, Dinter T, Yu PB, Kon N, Gu W, Takarada T, Greenblatt MB, and Shim JH. A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nat Commun. 2020 May 8;11(1):2289.

12. Jang HJ, Lim S, Kim JM, Yoon S, Lee CY, Hwang HJ, Shin JW, Shin KJ, Kim HY, Nam D, Yea K, Hirabayashi Y, Lee YJ, Chae YC, Sun PG, and Choi JH. Glucosylceramide synthase is a molecular switch of adipo-osteogenic balance through synergistic activation of PPARγ with GlcCer. FASEB J. 2020 Jan;34(1):1270-1287.

Space21 building, College of Sciences, Stem cell and regenerative medicine lab (1024)

02447 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, Republic of Korea

copyright (c) Department of Biology, College of Science, Kyung Hee University. All right Reserved 

02-961-2142

bottom of page